When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Researchers at the School of Chinese Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have found that ...

Wondering about minoxidil 10% or higher for hair loss? When it comes to this topical product, a higher strength doesn’t ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Interest in autonomous agents is skyrocketing. Here, CIOs from finance, retail, and healthcare discuss how they see the ...

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ...

Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.